BioTrinity 2010 Keynotes and Panel Discussions - April 12-14, 2010
Excellent plenary sessions and panel discussions will take place at BioTrinity 2010, featuring senior licensing professionals from global pharma such as Merck, BMS, Boehringer, GSK, Novartis, and Shire as well as VC's and Investment Banks such as Abingworth, SR One, MedImmune Ventures, KBC Peel Hunt and Piper Jaffray.
Our plenaries and panels feature international participation from professionals in the US, UK, Denmark, Germany, and Switzerland, with companies from over 10 countries represented among the audience.
The Panel Sessions will run along the following six themes:
“What Pharma Wants: Acquisition and Alliances”
“What's new in Licensing - Research, Option & Evaluation Deals”
“UK Healthcare Market 2010: Is the IPO Window Opening?”
“As the Investment Landscape Shifts: How to Raise Capital in a Changing World”
“What can be Built with Corporate Venture Funds”
“Avoiding the Cash Drought: Alternative Financing Strategies for Research-Led Companies”
The Shadow Business Minister, John Penrose MP, will open the conference at the Grand Opening and Reception on April 12.
| Day One - Tuesday 13th April 2010 | |
| 08:50-09:00 | Welcome and Opening Remarks: |
| Dr Jon Rees, OBN | |
|
|
|
| 09:10-10:30 | Investment Panel Discussion: As the Investment Landscape Shifts: How to Raise Capital in a Changing World. Gain insight from experts from Venture Capital and Investment Banking backgrounds. |
 |
Tim Haines, Partner, Abingworth Management (Chair) |
 |
Graziano Seghezzi, Partner, Sofinnova Partners |
 |
Ian Wainwright, Principal, Corporate Broking, Piper Jaffray |
 |
Marco Boorsma, Senior Analyst, Forbion Capital Partners |
 |
Kaasim Mahmood, Principal, Advent Ventures |
 |
Rebecca Todd, Investment Manager - Healthcare, Oxford Capital Partners |
|
|
|
| 11.00-12:00 | Investor Panel Discussion: What can be Built with Corporate Venture Funds? |
 |
Deborah Harland, Partner, SR One |
  |
Eva Jack, Managing Director, MedImmune Ventures |
 |
Graeme R Martin Ph.D., President and CEO, Takeda Research Investment, Inc. |
|
|
|
| Day Two - Wednesday 14th April 2010 | |
| 08:50-09:50 | Pharma Panel Discussion: What's new in Licensing - Research, Option & Evaluation Deals. |
 |
Fintan Walton, CEO, PharmaVentures (Chair) |
 |
Kate Burt, Director, Commercial Alliances and Transactions, GSK |
 |
Matthew Walls, CEO, Epistem plc |
 |
Graham Pay, Strategic Alliance Manager - Respiratory Diseases, Novartis |
 |
Tim Sparey, Director of Business Development, Proximagen plc |
 |
Barry Kenny, CBO, Heptares Therapeutics |
|
|
|
| 09:50-10.30 | Investor Panel Discussion: UK Healthcare Market 2010: Is the IPO Window Opening? |
 |
James Steel – Director, Corporate Finance, KBC Peel Hunt |
|
Paul Cuddon - Analyst, KBC Peel Hunt |
 |
Jan Rutherford - Principal, Scottish Equity Partners (SEP) |
 |
Ian Paling - CEO and Exec Chairman, CellCoTec |
 |
Ian Garland - CEO, Vernalis plc |
|
|
|
| 11:00-12.00 | What Pharma Wants: Acquisition and Alliances |
 |
Lubor Gaal, Director, External Science Technology & Licensing, Bristol Myers-Squibb |
 |
Rob Pinnock, Director, Scientific & Academic Liaison Licensing and External Research, Merck |
 |
David Colpman, Director of Business Development, Shire |
 |
Dr. Christopher Meade, Head of Global Licensing for Respiratory, Boehringer Ingelheim |
 |
Alan G. Lamont - Director, Science and Technology Alliances, AstraZeneca |
|
|
|
| 12:00-12.30 | Avoiding the Cash Drought: Alternative Financing Strategies for Research-Led Companies |
 |
James Gubbins, Partner, Morrison & Foerster |
 |
Ken Macleod, Partner, Paul Capital Partners |
 |
Richard Honey, Partner, ETV Capital Limited |
| |
Anand Sambasivan, Partner, Darwin Strategic |
BioTrinity 2009 Keynotes and Panels
| Day One - Thursday 2nd April 2009 | |
| 08:50-09:00 | Welcome and Opening Remarks: |
| Dr Jon Rees, OBN | |
| 09:00-09:10 | VIP Address |
| Professor Malcolm Grant, Business Ambassador, UKTI | |
| 09:10-09:50 | Panel Discussion: Thiakis, Piramed and Arrow - Returning half a billion dollars of value to investors: why VCís should invest in UK biotech companies. Learn from the experiences of three recently acquired biotechs. |
 |
Ken Powell, Former CEO, Arrow Therapeutics |
| John Burt, CEO, Thiakis | |
|
David Knowles, Former CSO, Piramed |
|
Mike Wort, MD, De Facto Communications (chair) |
| 09:50-10:30 | VC Panel Discussion: Successful Fundraising in Tough Economic Climes (Oxford Suite) |
 |
Dr. Regina Hodits , Partner, Atlas Venture (UK) |
 |
Martin Edwards, Senior Partner, Novo Ventures, Novo A/S (Denmark) |
 |
Graeme R Martin Ph.D., President & CEO Takeda Research Investment, Inc. (USA) |
 |
Allison Robbins, Senior Associate, Genzyme Ventures (US) |
 |
Sam Fazeli PhD, Head of European Equity Research Piper Jaffray Ltd |
 |
David Mott, Investment Director Oxford Capital Partners (UK, Panel Chair) |
| 11:00 - 11:20 | Plenary Talk: What Genzyme is looking for in the Oncology Pipeline |
|
Paul Drohan, Vice President and General Manager, Genzyme UK and Ireland |
| Day Two - Friday 3rd April 2009 | |
| 09:00-09:20 | Plenary Talk: EUSA Pharma and Philosophy, Building a Leading Transatlantic Speciality Pharma |
| Key Notes from the CEO of the most successful fundraising emerging company in the sector, which has already raised $295m in its first few years of existence. Reflecting on the philosophy required for success. | |
 |
Bryan Morton, CEO, EUSA Pharma |
| 09:20-09:30 | Key Developments: Tailoring Real Estate Solutions in Challenging Times |
| Director of the UK's key property developer for bioscience communities describes the next wave of affordable space for biotech and medtech companies in the Oxford BioCluster | |
 |
James Dipple, Director, MEPC Milton Park |
| 09:30-09:45 | Plenary Talk: What Merck Wants |
 |
Rob Pinnock, Director, Licensing and External Research, Merck Sharp Dohme (UK subsiduary of Merck & Co. Inc.) |
| 09:45-10:00 | Plenary Talk: A Perspective on the Innovative Medicines Initiative (IMI) |
 |
Jackie Hunter, SVP & Head of Neurology and Gastrointestinal CEDD GSK |
| 11:00-11.40 | Panel Discussion: Successful Deal Making in Tough Economic Climes (Oxford Suite) |
 |
Nigel Sheail, VP Global Head of Licensing, Pharma Partnering Roche |
 |
Esteban Pombo-Villar, Head of Strategic Alliance Management, Europe Novartis Institutes of BioMedical Research |
|
Kate Burt, Director, Transactions, Worldwide Business Development GSK |
 |
Ian Nicholson, CEO Chroma Therapeutics |
 |
Jane Dancer, Vice President Business Development Cellzome Limited |
 |
Fintan Walton,, CEO PharmaVentures |
| 13:30-14:00 | Panel Discussion: Where Oxford's Great Minds Meet: How to be Successful in Biotech (Oxford Suite) |
| Some of Oxfordís most successful biotech entrepreneurs talk about the key factors in how to be successful in biotech, what has been key to their success, what they think will be the key to success in the future and for the pundits, which emerging companies they believe will be the most successful. | |
 |
Anker Lundemose PhD MD, President (OSI) Prosidion |
 |
Dr Mark Ashton, COO Evotec |
 |
Bruce Savage, CEO CMP Therapeutics |
|
David Laskow-Pooley, CEO, PharmaFor (chair) |
| 15.00-15.20 | Plenary Talk - The Final Word: BioCentury Economic Forecast for Biotech in Europe |
 |
Mike Ward, Senior Editor (Europe), BioCentury |
